ReviewCureus2024
Nonfactor Therapies in Hemophilia A: An Essential Drug Entity.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolving landscape of haemophilia care in India: Balancing innovation, access, and sustainability.The Indian journal of medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inequity in the access to effective therapies for rare diseases, such as hemophilia A, is a significant concern in resource-limited settings. Including necessary medications in the essential drug list can ensure that populations have access to safe and affordable treatments. Emicizumab, a nonfactor therapy, addresses many of the challenges associated with traditional factor replacement for hemophilia A, including frequent administration and the risk of inhibitor development. Studies in India show that emicizumab is cost-effective and clinically beneficial. The inclusion of emicizumab in the National Health Mission's (NHM) Essential Drug List (India) would improve treatment access and adherence, reduce healthcare burden, and improve outcomes for patients, particularly those with high bleeding rates and poor accessibility to care. Moreover, it will ensure the continuity of therapy for all existing patients who have been on emicizumab supported by the NHM in the last four years. This review aims to consolidate evidence regarding the current status of care and the benefits of emicizumab in India to highlight the importance of the addition of emicizumab to NHM's Essential Drug List.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.